Bruce Spohler
Analyst · Mickey Schleien with Ladenburg
Thank you, Rich. I'd like to start by making on overall observation that our portfolio companies, in general, are optimistic about their respective businesses. However, they continue to be cautious regarding the macro and economic uncertainties. One general theme that emerges is stable performance and steady deleveraging in an environment of muted top line growth and a focus on cost efficiencies. Our investment priority remains to invest in recession-resilient, stable companies that can generate cash flow and reduce leverage throughout an economic cycle. Let me give you an overview of the portfolio. At the end of the third quarter, the fair market value of our investment portfolio was approximately $1.2 billion. The fair value weighted average yield on our income-producing investments was approximately 14%, consistent with the prior quarter. As of 9/30, 41% of the fair value of our portfolio was in secured assets. We have investments in 41 companies, operating across 23 industries. The weighted average investment risk rating of the portfolio remained at approximately 2, measured at fair market value at the end of the quarter, based on our 1 to 4 risk rating scale, with 1 representing the least amount of risk. Now I would like to provide you an update on a few of our existing portfolio companies. DS Waters. Since our last update, we can report that the company continues to perform in line with expectations. Customer growth has driven both increased revenues and EBITDA over the prior year. In addition, the integration of the coffee acquisition is on schedule, and cost efficiencies are being realized as anticipated by management. Our third-party independent valuation firm valued our investment in the company's second lien loan at 103.5% of par, and our investment in our senior preferred units at approximately $0.85, or $0.846, to be exact. DS Waters' strong operating performance, in conjunction with strong market conditions, has resulted in its first and second lien term loans being quoted at a significant premium to par and in line with their respective call prices, reflecting the market's view of the company's debt securities. Now let me turn to our non-accrual assets. DirectBuy. In Q4 2011, we placed DirectBuy on non-accrual. We continue to be in active dialogue with the sponsor, bondholders and company's management, concerning a restructuring transaction that we expect to take place during Q4. DirectBuy is the largest domestic franchisor of membership-based buying centers, which allows customers to purchase products direct from manufacturers. As of September 30, JPMorgan, the sole book runner of the existing notes, had this asset quoted at $0.20 of par, resulting in a fair value for our investment of $5 million. We believe this valuation reflects the underlying fundamentals of DirectBuy's business and expect this asset to return to accrual status during this quarter. Granite Global. Last quarter, we placed Granite Global on non-accrual status. The company is the leading provider of outsourced insurance-related services such as claims adjusting for property, casualty and auto lines to Canadian-based insurance companies. We continue to be in active dialogue with the sponsor and the company's other lenders. At 9/30, our third-party valuation firm valued this asset that $0.85 of par, resulting in a fair value of the $15.7 million. We believe this valuation reflects the underlying fundamentals of Granite's business, including its improving trends, and we continue to believe that the investment will return to full accrual status during this quarter. Now let me touch on one of our 2007 investments, Weetabix. Last quarter, we announced that Weetabix had agreed to be acquired by China's Bright Foods. The company expects the transaction to close today, at which time, our $55.7 million investment is expected to be repaid in full. These pre-credit crisis legacy investments had some of the lowest yields in our portfolio. The full repayment will reduce the portfolio's non-U.S. dollar currency exposure by more than half. In addition, Weetabix's repayment will reduce our PIK exposure and allow Solar to reinvest the proceeds in cash pay loans at higher yields across the portfolio. Weetabix had a weighted average mark in the mid-50s back in the trough of December 2008. With the benefit of our patient capital base, we were able to realize a high-single-digit IRR on the Weetabix investment. I'd also like to bring your attention to a name change regarding one of our investments listed on our Q3 schedule of investments, Allegis Technologies, which is a carve-out from Fidelity. This investment had previously been named FIS Health Care Holdings. Just to remind you, Allegis is a leading provider of software services and card-based technologies for health care benefits. In August, we funded a $28 million mezzanine investment, offering an all-in yield in the high 12% area at total leverage levels of under 5x at 4.7. On the origination front, during the third quarter, we committed approximately $27 million par value into 2 new and 1 existing portfolio companies. Our principal repayments in sales totaled approximately $71.5 million for the quarter. Now I'll provide some color on some of the activity. We committed CAD 10 million in a first lien term loan investment to easyfinancial Services, which is a consumer lending subsidiary of easyhome, a publicly traded business in Toronto, which is a leading merchandise leasing company. These funds were used to support the company's strategy to grow its consumer loan portfolio. Our loan, which is a first lien loan, was structured with a yield in the mid-12s. We expect to increase our investment over time in conjunction with the projected growth of the borrower's accounts receivable days. In addition, we invested approximately $17 million in a secondary market purchase of a unit tranche loan to T&D Solutions Holdings. T&D is a leading maintenance provider for electric transmission and distribution lines, primarily in the Gulf Coast and South Mid-Atlantic regions of the U.S. As a result of our relationship with the sponsor, we were able to conduct primary due diligence on this secondary purchase. It's levered under 3x and offers a 13% cash coupon. During the quarter, our portfolio experienced 2 repayments. The first was a full repayment at a premium to par of our $35 million secured term loan to National Vision, a leading value-oriented optical retailer owned by Berkshire Partners. Also, during the third quarter, Asurion, the leading provider of a cell phone warranty services, refinanced approximately 55% of its second lien loan, which resulted in a repayment to Solar of $22.5 million at $1.03 on par. Portfolio continues to hold an $18.5 million fair value remaining exposure to the second lien tranche, in addition to our approximately $13 million investment at fair value in Asurion's subordinated debt. Solar originally invested in Asurion back in 2007 and had invested in this credit multiple times over the last several years. The company continues to perform exceptionally well. Now I'd like to turn the call back over to Michael.